Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
Atogepant for preventing migraine | TA973 | | |
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | DG58 | | |
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments | TA970 | | |
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
Artificial intelligence (AI)-derived software to help clinical decision making in stroke | DG57 | | |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
Endometriosis: diagnosis and management | NG73 | | |
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |
Twin and triplet pregnancy | NG137 | | |
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA963 | | |
Kurin Lock for blood culture collection | MTG77 | | |
GaitSmart rehabilitation exercise programme for gait and mobility issues | MTG78 | | |
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
Suspected sepsis: recognition, diagnosis and early management | NG51 | | |
Neonatal infection: antibiotics for prevention and treatment | NG195 | | |
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | NG240 | | |
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
Lung cancer: diagnosis and management | NG122 | | |
Vitamin B12 deficiency in over 16s: diagnosis and management | NG239 | | |
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
Tuberculosis | NG33 | | |
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
Caesarean birth | NG192 | | |
Devices for remote monitoring of Parkinson's disease | DG51 | | |
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
Sebelipase alfa for treating Wolman disease | HST30 | | |
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
Bipolar disorder: assessment and management | CG185 | | |
Targeted-release budesonide for treating primary IgA nephropathy | TA937 | | |
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
Empagliflozin for treating chronic kidney disease | TA942 | | |
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
Risdiplam for treating spinal muscular atrophy | TA755 | | |
Cardiovascular disease: risk assessment and reduction, including lipid modification | NG238 | | |
Velmanase alfa for treating alpha-mannosidosis | HST29 | | |
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
Acne vulgaris: management | NG198 | | |
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
Transient loss of consciousness ('blackouts') in over 16s | CG109 | | |
Hypertension in adults: diagnosis and management | NG136 | | |
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management | NG237 | | |
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
Jaundice in newborn babies under 28 days | CG98 | | |
Pneumonia in adults: diagnosis and management | CG191 | | |
Ranibizumab for treating diabetic macular oedema | TA274 | | |
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
Tirzepatide for treating type 2 diabetes | TA924 | | |
Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
Baricitinib for treating severe alopecia areata | TA926 | | |
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
Stroke rehabilitation in adults | NG236 | | |
Rimegepant for treating migraine | TA919 | | |
Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
Ruxolitinib for treating polycythaemia vera | TA921 | | |
Daridorexant for treating long-term insomnia | TA922 | | |
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
Thyroid disease: assessment and management | NG145 | | |
Bimekizumab for treating axial spondyloarthritis | TA918 | | |
Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
Bimekizumab for treating active psoriatic arthritis | TA916 | | |
Urinary incontinence in neurological disease: assessment and management | CG148 | | |
Ovarian cancer: recognition and initial management | CG122 | | |
Suspected cancer: recognition and referral | NG12 | | |
Suspected neurological conditions: recognition and referral | NG127 | | |
Hearing loss in adults: assessment and management | NG98 | | |
Intrapartum care | NG235 | | |
Acute kidney injury: prevention, detection and management | NG148 | | |
Birch bark extract for treating epidermolysis bullosa | HST28 | | |
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
Cirrhosis in over 16s: assessment and management | NG50 | | |
Spinal metastases and metastatic spinal cord compression | NG234 | | |
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
Semaglutide for managing overweight and obesity | TA875 | | |
Otitis media with effusion in under 12s | NG233 | | |
Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care | DG56 | | |
Ectopic pregnancy and miscarriage: diagnosis and initial management | NG126 | | |
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | NG158 | | |
Obesity: identification, assessment and management | CG189 | | |
Afamelanotide for treating erythropoietic protoporphyria | HST27 | | |
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
KardiaMobile for detecting atrial fibrillation | MTG64 | | |
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer | TA909 | | |
AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images | DG55 | | |
Rimegepant for preventing migraine | TA906 | | |
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
Oesophago-gastric cancer: assessment and management in adults | NG83 | | |
Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care | DG48 | | |
Atopic eczema in under 12s: diagnosis and management | CG57 | | |
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
Bulevirtide for treating chronic hepatitis D | TA896 | | |
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
Transperineal biopsy for diagnosing prostate cancer | DG54 | | |
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers | DG52 | | |
MRI fusion biopsy systems for diagnosing prostate cancer | DG53 | | |
Head injury: assessment and early management | NG232 | | |
Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
Diabetes (type 1 and type 2) in children and young people: diagnosis and management | NG18 | | |
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management | CG104 | | |
Tezepelumab for treating severe asthma | TA880 | | |
Lumasiran for treating primary hyperoxaluria type 1 | HST25 | | |
Onasemnogene abeparvovec for treating spinal muscular atrophy | HST15 | | |
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency | HST26 | | |
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | HST24 | | |
Hypertension in pregnancy: diagnosis and management | NG133 | | |
AposHealth for knee osteoarthritis | MTG76 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
UrgoStart for treating diabetic foot ulcers and leg ulcers | MTG42 | | |
Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
Asfotase alfa for treating paediatric-onset hypophosphatasia | HST23 | | |
Eptinezumab for preventing migraine | TA871 | | |
Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene | HST22 | | |
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) | TA869 | | |
Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | NG231 | | |
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
Delirium: prevention, diagnosis and management in hospital and long-term care | CG103 | | |
Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
Tobacco: preventing uptake, promoting quitting and treating dependence | NG209 | | |
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education | NG213 | | |
MRI-based technologies for assessing non-alcoholic fatty liver disease | DG50 | | |
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
Hip fracture: management | CG124 | | |
Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
Thyroid cancer: assessment and management | NG230 | | |
Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
Fetal monitoring in labour | NG229 | | |
Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
Esketamine nasal spray for treatment-resistant depression | TA854 | | |
Memokath 051 Ureter stent for ureteric obstruction | MTG75 | | |
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
Optilume for treating recurrent bulbar urethral strictures | MTG73 | | |
GreenLight XPS for treating benign prostatic hyperplasia | MTG74 | | |
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
Fractures (complex): assessment and management | NG37 | | |
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management | NG228 | | |
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) | TA839 | | |
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
Advocacy services for adults with health and social care needs | NG227 | | |
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
Osteoarthritis in over 16s: diagnosis and management | NG226 | | |
Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) | TA834 | | |
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer | MTG72 | | |
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA823 | | |
Neuropad for detecting preclinical diabetic peripheral neuropathy | MTG38 | | |
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas | CG118 | | |
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
Self-harm: assessment, management and preventing recurrence | NG225 | | |
Faecal microbiota transplant for recurrent Clostridioides difficile infection | MTG71 | | |
Brolucizumab for treating diabetic macular oedema | TA820 | | |
iFuse for treating chronic sacroiliac joint pain | MTG39 | | |
Avalglucosidase alfa for treating Pompe disease | TA821 | | |
Type 1 diabetes in adults: diagnosis and management | NG17 | | |
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
SecurAcath for securing percutaneous catheters | MTG34 | | |
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
PLGF-based testing to help diagnose suspected preterm pre-eclampsia | DG49 | | |
Melanoma: assessment and management | NG14 | | |
Urinary tract infection in under 16s: diagnosis and management | NG224 | | |
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites | MTG9 | | |
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
Setmelanotide for treating obesity caused by LEPR or POMC deficiency | HST21 | | |
Social, emotional and mental wellbeing in primary and secondary education | NG223 | | |
MiraQ for assessing graft flow during coronary artery bypass graft surgery | MTG8 | | |
Teduglutide for treating short bowel syndrome | TA804 | | |
Depression in adults: treatment and management | NG222 | | |
Type 2 diabetes in adults: management | NG28 | | |
Faricimab for treating diabetic macular oedema | TA799 | | |
Faricimab for treating wet age-related macular degeneration | TA800 | | |
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
Multiple sclerosis in adults: management | NG220 | | |
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
Reducing sexually transmitted infections | NG221 | | |
Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
Preterm labour and birth | NG25 | | |
Gout: diagnosis and management | NG219 | | |
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
Peristeen Plus transanal irrigation system for managing bowel dysfunction | MTG36 | | |
Thopaz+ portable digital system for managing chest drains | MTG37 | | |
Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
Social work with adults experiencing complex needs | NG216 | | |
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
Romosozumab for treating severe osteoporosis | TA791 | | |
Sleepio to treat insomnia and insomnia symptoms | MTG70 | | |
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
Vaccine uptake in the general population | NG218 | | |
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over | HST20 | | |
Epilepsies in children, young people and adults | NG217 | | |
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
Elosulfase alfa for treating mucopolysaccharidosis type 4A | HST19 | | |
Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults | NG215 | | |
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management | NG128 | | |
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
myCOPD for managing chronic obstructive pulmonary disease | MTG68 | | |
UroShield for preventing catheter-associated urinary tract infections | MTG69 | | |
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) | DG47 | | |
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
Atidarsagene autotemcel for treating metachromatic leukodystrophy | HST18 | | |
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
Integrated health and social care for people experiencing homelessness | NG214 | | |
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
Otitis media (acute): antimicrobial prescribing | NG91 | | |
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
Dapagliflozin for treating chronic kidney disease | TA775 | | |
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
Prontosan for treating acute and chronic wounds | MTG67 | | |
3C Patch for treating diabetic foot ulcers | MTG66 | | |
Mental wellbeing at work | NG212 | | |
PredictSURE IBD and IBDX to guide treatment of Crohn's disease | DG45 | | |
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | DG46 | | |
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
Odevixibat for treating progressive familial intrahepatic cholestasis | HST17 | | |
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) | TA762 | | |
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
Fremanezumab for preventing migraine | TA764 | | |
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
Palforzia for treating peanut allergy in children and young people | TA769 | | |
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care | MTG65 | | |
Glaucoma: diagnosis and management | NG81 | | |
Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA761 | | |
Rehabilitation after traumatic injury | NG211 | | |
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA760 | | |
Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
Headaches in over 12s: diagnosis and management | CG150 | | |
Endo-SPONGE for treating low rectal anastomotic leak | MTG63 | | |
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA756 | | |
Colorectal cancer | NG151 | | |
Prostate cancer: diagnosis and management | NG131 | | |
Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections | MTG62 | | |
Pelvic floor dysfunction: prevention and non-surgical management | NG210 | | |
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
Synergo for non-muscle-invasive bladder cancer | MTG61 | | |
Fever in under 5s: assessment and initial management | NG143 | | |
Givosiran for treating acute hepatic porphyria | HST16 | | |
Chronic kidney disease: assessment and management | NG203 | | |
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea | DG44 | | |
Acute heart failure: diagnosis and management | CG187 | | |
Heart valve disease presenting in adults: investigation and management | NG208 | | |
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
Inducing labour | NG207 | | |
Selpercatinib for treating advanced thyroid cancer with RET alterations | TA742 | | |
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management | NG206 | | |
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
Looked-after children and young people | NG205 | | |
Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography | MTG60 | | |
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
Babies, children and young people's experience of healthcare | NG204 | | |
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | NG202 | | |
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
Antenatal care | NG201 | | |
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | | |
Bronchiolitis in children: diagnosis and management | NG9 | | |
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
Clostridioides difficile infection: antimicrobial prescribing | NG199 | | |
ENDURALIFE powered CRT-D devices for treating heart failure | MTG33 | | |
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
Ixekizumab for treating axial spondyloarthritis | TA718 | | |
Secukinumab for treating non-radiographic axial spondyloarthritis | TA719 | | |
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
Atrial fibrillation: diagnosis and management | NG196 | | |
Plus Sutures for preventing surgical site infection | MTG59 | | |
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
Patient experience in adult NHS services: improving the experience of care for people using adult NHS services | CG138 | | |
Shared decision making | NG197 | | |
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
Autism spectrum disorder in adults: diagnosis and management | CG142 | | |
Autism spectrum disorder in under 19s: support and management | CG170 | | |
Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
Heavy menstrual bleeding: assessment and management | NG88 | | |
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography | MTG32 | | |
Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers | MTG20 | | |
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA696 | | |
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia | MTG58 | | |
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
Postnatal care | NG194 | | |
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain | NG193 | | |
Danis stent for acute oesophageal variceal bleeding | MTG57 | | |
Anakinra for treating Still's disease | TA685 | | |
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
Cannabis-based medicinal products | NG144 | | |
Asthma: diagnosis, monitoring and chronic asthma management | NG80 | | |
QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography | DG43 | | |
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
Erenumab for preventing migraine | TA682 | | |
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
Alpha-Stim AID for anxiety disorders | MTG56 | | |
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing | NG190 | | |
Safeguarding adults in care homes | NG189 | | |
Metreleptin for treating lipodystrophy | HST14 | | |
Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
Leukomed Sorbact for preventing surgical site infection | MTG55 | | |
Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
Brain tumours (primary) and brain metastases in over 16s | NG99 | | |
The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal | MTG54 | | |
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
The PLASMA system for transurethral resection and haemostasis of the prostate | MTG53 | | |
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
Pancreatitis | NG104 | | |
Diabetes in pregnancy: management from preconception to the postnatal period | NG3 | | |
Eating disorders: recognition and treatment | NG69 | | |
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
Peripheral arterial disease: diagnosis and management | CG147 | | |
Low back pain and sciatica in over 16s: assessment and management | NG59 | | |
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA663 | | |
Liraglutide for managing overweight and obesity | TA664 | | |
Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
Zio XT for detecting cardiac arrhythmias | MTG52 | | |
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
Acute coronary syndromes | NG185 | | |
Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
Guidance on the use of coronary artery stents | TA71 | | |
Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
Carfilzomib for previously treated multiple myeloma | TA657 | | |
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
Galcanezumab for preventing migraine | TA659 | | |
Human and animal bites: antimicrobial prescribing | NG184 | | |
Testing strategies for Lynch syndrome in people with endometrial cancer | DG42 | | |
Volanesorsen for treating familial chylomicronaemia syndrome | HST13 | | |
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
SEM Scanner 200 for preventing pressure ulcers | MTG51 | | |
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
Rheumatoid arthritis in adults: management | NG100 | | |
Behaviour change: digital and mobile health interventions | NG183 | | |
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
Naldemedine for treating opioid-induced constipation | TA651 | | |
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
Neuropathic pain in adults: pharmacological management in non-specialist settings | CG173 | | |
Insect bites and stings: antimicrobial prescribing | NG182 | | |
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA648 | | |
Axonics sacral neuromodulation system for treating refractory overactive bladder | MTG50 | | |
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke | DG41 | | |
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
Avelumab with axitinib for untreated advanced renal cell carcinoma | TA645 | | |
High-sensitivity troponin tests for the early rule out of NSTEMI | DG40 | | |
Anaphylaxis: assessment and referral after emergency treatment | CG134 | | |
Perioperative care in adults | NG180 | | |
Rehabilitation for adults with complex psychosis | NG181 | | |
Surgical site infections: prevention and treatment | NG125 | | |
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
Entrectinib for treating NTRK fusion-positive solid tumours | TA644 | | |
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia | MTG49 | | |
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) | DG39 | | |
Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
Generalised anxiety disorder and panic disorder in adults: management | CG113 | | |
Intravenous fluid therapy in children and young people in hospital | NG29 | | |
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
Joint replacement (primary): hip, knee and shoulder | NG157 | | |
Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
PneuX to prevent ventilator-associated pneumonia | MTG48 | | |
Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
Abdominal aortic aneurysm: diagnosis and management | NG156 | | |
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
Tinnitus: assessment and management | NG155 | | |
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
Impetigo: antimicrobial prescribing | NG153 | | |
Neonatal parenteral nutrition | NG154 | | |
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi | DG20 | | |
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
Patiromer for treating hyperkalaemia | TA623 | | |
Sotagliflozin with insulin for treating type 1 diabetes | TA622 | | |
Antenatal and postnatal mental health: clinical management and service guidance | CG192 | | |
Episcissors-60 for mediolateral episiotomy | MTG47 | | |
Leg ulcer infection: antimicrobial prescribing | NG152 | | |
Supporting adult carers | NG150 | | |
Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C | MTG27 | | |
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
Indoor air quality at home | NG149 | | |
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
Menopause: diagnosis and management | NG23 | | |
gammaCore for cluster headache | MTG46 | | |
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 | HST12 | | |
Diverticular disease: diagnosis and management | NG147 | | |
Workplace health: long-term sickness absence and capability to work | NG146 | | |
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast | DG37 | | |
Rapid tests for group A streptococcal infections in people with a sore throat | DG38 | | |
Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA611 | | |
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | CG184 | | |
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
End of life care for adults: service delivery | NG142 | | |
Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
Diabetic foot problems: prevention and management | NG19 | | |
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations | HST11 | | |
Gastro-oesophageal reflux disease in children and young people: diagnosis and management | NG1 | | |
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea | TA605 | | |
EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing | MTG12 | | |
Familial hypercholesterolaemia: identification and management | CG71 | | |
Idelalisib for treating refractory follicular lymphoma | TA604 | | |
Cellulitis and erysipelas: antimicrobial prescribing | NG141 | | |
Abortion care | NG140 | | |
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
Tegaderm CHG securement dressing for vascular access sites in critically ill adults | MTG25 | | |
Pneumonia (community-acquired): antimicrobial prescribing | NG138 | | |
Pneumonia (hospital-acquired): antimicrobial prescribing | NG139 | | |
Attention deficit hyperactivity disorder: diagnosis and management | NG87 | | |
Benralizumab for treating severe eosinophilic asthma | TA565 | | |
Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
Patisiran for treating hereditary transthyretin amyloidosis | HST10 | | |
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) | TA594 | | |
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | NG89 | | |
Alcohol interventions in secondary and further education | NG135 | | |
PICO negative pressure wound dressings for closed surgical incisions | MTG43 | | |
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
Chronic obstructive pulmonary disease in over 16s: diagnosis and management | NG115 | | |
End of life care for infants, children and young people with life-limiting conditions: planning and management | NG61 | | |
Nusinersen for treating spinal muscular atrophy | TA588 | | |
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
Motor neurone disease: assessment and management | NG42 | | |
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis | DG36 | | |
Bisphosphonates for treating osteoporosis | TA464 | | |
Long-acting reversible contraception | CG30 | | |
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
Depression in children and young people: identification and management | NG134 | | |
Urinary incontinence and pelvic organ prolapse in women: management | NG123 | | |
Ambu aScope4 Broncho for use in unexpected difficult airways | MTG14 | | |
Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
Endocuff Vision for assisting visualisation during colonoscopy | MTG45 | | |
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters | MTG24 | | |
Hyperparathyroidism (primary): diagnosis, assessment and initial management | NG132 | | |
Inotersen for treating hereditary transthyretin amyloidosis | HST9 | | |
Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
Curos for preventing infections when using needleless connectors | MTG44 | | |
Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care | DG35 | | |
Crohn's disease: management | NG129 | | |
Ulcerative colitis: management | NG130 | | |
Intrapartum care for women with existing medical conditions or obstetric complications and their babies | NG121 | | |
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
Specialist neonatal respiratory care for babies born preterm | NG124 | | |
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
The Debrisoft monofilament debridement pad for use in acute or chronic wounds | MTG17 | | |
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
Cough (acute): antimicrobial prescribing | NG120 | | |
Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain | MTG41 | | |
Cerebral palsy in adults | NG119 | | |
Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers | MTG40 | | |
Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms | MTG10 | | |
Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
Renal and ureteric stones: assessment and management | NG118 | | |
Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing | NG117 | | |
Vandetanib for treating medullary thyroid cancer | TA550 | | |
Post-traumatic stress disorder | NG116 | | |
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing | NG114 | | |
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
Urinary tract infection (catheter-associated): antimicrobial prescribing | NG113 | | |
Padeliporfin for untreated localised prostate cancer | TA546 | | |
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
Urinary tract infection (lower): antimicrobial prescribing | NG109 | | |
Prostatitis (acute): antimicrobial prescribing | NG110 | | |
Pyelonephritis (acute): antimicrobial prescribing | NG111 | | |
Urinary tract infection (recurrent): antimicrobial prescribing | NG112 | | |
Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
Myeloma: diagnosis and management | NG35 | | |
Lyme disease | NG95 | | |
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
Burosumab for treating X-linked hypophosphataemia in children and young people | HST8 | | |
Renal replacement therapy and conservative management | NG107 | | |
Decision-making and mental capacity | NG108 | | |
Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta | MTG16 | | |
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
Chronic heart failure in adults: diagnosis and management | NG106 | | |
Preventing suicide in community and custodial settings | NG105 | | |
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
Flu vaccination: increasing uptake | NG103 | | |
Dinutuximab beta for treating neuroblastoma | TA538 | | |
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
Community pharmacies: promoting health and wellbeing | NG102 | | |
Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
Biomarker tests to help diagnose preterm labour in women with intact membranes | DG33 | | |
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA529 | | |
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
Dementia: assessment, management and support for people living with dementia and their carers | NG97 | | |
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over | NG36 | | |
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I | DG32 | | |
Tocilizumab for treating giant cell arteritis | TA518 | | |
Care and support of people growing older with learning disabilities | NG96 | | |
Learning disabilities and behaviour that challenges: service design and delivery | NG93 | | |
Emergency and acute medical care in over 16s: service delivery and organisation | NG94 | | |
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
Cabozantinib for treating medullary thyroid cancer | TA516 | | |
Physical activity and the environment | NG90 | | |
Brodalumab for treating moderate to severe plaque psoriasis | TA511 | | |
Tivozanib for treating advanced renal cell carcinoma | TA512 | | |
Obinutuzumab for untreated advanced follicular lymphoma | TA513 | | |
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | TA508 | | |
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | | |
People's experience in adult social care services: improving the experience of care and support for people using adult social care services | NG86 | | |
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency | HST7 | | |
Pancreatic cancer in adults: diagnosis and management | NG85 | | |
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | | |
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | TA161 | | |
Pirfenidone for treating idiopathic pulmonary fibrosis | TA504 | | |
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
Ibrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | | |
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
Sore throat (acute): antimicrobial prescribing | NG84 | | |
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | | |
Glecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | | |
Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
Age-related macular degeneration | NG82 | | |
Golimumab for treating non-radiographic axial spondyloarthritis | TA497 | | |
Autism spectrum disorder in under 19s: recognition, referral and diagnosis | CG128 | | |
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) | DG14 | | |
Naltrexone–bupropion for managing overweight and obesity | TA494 | | |
Vismodegib for treating basal cell carcinoma | TA489 | | |
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
Tests in secondary care to identify people at high risk of ovarian cancer | DG31 | | |
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | TA488 | | |
Sarilumab for moderate to severe rheumatoid arthritis | TA485 | | |
Aflibercept for treating choroidal neovascularisation | TA486 | | |
Sinusitis (acute): antimicrobial prescribing | NG79 | | |
Cataracts in adults: management | NG77 | | |
Cystic fibrosis: diagnosis and management | NG78 | | |
Hepatitis B (chronic): diagnosis and management | CG165 | | |
Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
Child maltreatment: when to suspect maltreatment in under 18s | CG89 | | |
Child abuse and neglect | NG76 | | |
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
Reslizumab for treating severe eosinophilic asthma | TA479 | | |
Faltering growth: recognition and management of faltering growth in children | NG75 | | |
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
Intermediate care including reablement | NG74 | | |
Type 2 diabetes: prevention in people at high risk | PH38 | | |
Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
Fertility problems: assessment and treatment | CG156 | | |
Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
Psoriasis: assessment and management | CG153 | | |
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
Vitamin D: supplement use in specific population groups | PH56 | | |
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
Advanced breast cancer: diagnosis and treatment | CG81 | | |
Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
Developmental follow-up of children and young people born preterm | NG72 | | |
Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment | MTG2 | | |
Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | CG32 | | |
Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
Parkinson's disease in adults | NG71 | | |
Constipation in children and young people: diagnosis and management | CG99 | | |
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners | DG3 | | |
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
Air pollution: outdoor air quality and health | NG70 | | |
Eliglustat for treating type 1 Gaucher disease | HST5 | | |
Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis | DG29 | | |
Obesity: working with local communities | PH42 | | |
Spondyloarthritis in over 16s: diagnosis and management | NG65 | | |
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
Idiopathic pulmonary fibrosis in adults: diagnosis and management | CG163 | | |
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy | DG28 | | |
Intravenous fluid therapy in adults in hospital | CG174 | | |
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
Antisocial behaviour and conduct disorders in children and young people: recognition and management | CG158 | | |
Alcohol-use disorders: diagnosis and management of physical complications | CG100 | | |
Sexually transmitted infections: condom distribution schemes | NG68 | | |
Irritable bowel syndrome in adults: diagnosis and management | CG61 | | |
Managing medicines for adults receiving social care in the community | NG67 | | |
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
Patient group directions | MPG2 | | |
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
Mental health of adults in contact with the criminal justice system | NG66 | | |
Ustekinumab for treating active psoriatic arthritis | TA340 | | |
Ustekinumab for the treatment of adults with moderate to severe psoriasis | TA180 | | |
Molecular testing strategies for Lynch syndrome in people with colorectal cancer | DG27 | | |
Migalastat for treating Fabry disease | HST4 | | |
Drug misuse prevention: targeted interventions | NG64 | | |
Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
Apremilast for treating active psoriatic arthritis | TA433 | | |
Healthcare-associated infections: prevention and control in primary and community care | CG139 | | |
HumiGard for preventing inadvertent perioperative hypothermia | MTG31 | | |
Osteoporosis: assessing the risk of fragility fracture | CG146 | | |
Cerebral palsy in under 25s: assessment and management | NG62 | | |
Antimicrobial stewardship: changing risk-related behaviours in the general population | NG63 | | |
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation | CG135 | | |
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
Hypothermia: prevention and management in adults having surgery | CG65 | | |
Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
XprESS multi sinus dilation system for treating chronic sinusitis | MTG30 | | |
HIV testing: increasing uptake among people who may have undiagnosed HIV | NG60 | | |
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis | CG95 | | |
Coexisting severe mental illness and substance misuse: community health and social care services | NG58 | | |
Spasticity in under 19s: management | CG145 | | |
Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
High-throughput non-invasive prenatal testing for fetal RHD genotype | DG25 | | |
Physical health of people in prison | NG57 | | |
Psychosis and schizophrenia in children and young people: recognition and management | CG155 | | |
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | TA407 | | |
Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
Multimorbidity: clinical assessment and management | NG56 | | |
Harmful sexual behaviour among children and young people | NG55 | | |
Mental health problems in people with learning disabilities: prevention, assessment and management | NG54 | | |
Transition between inpatient mental health settings and community or care home settings | NG53 | | |
Stable angina: management | CG126 | | |
Acute upper gastrointestinal bleeding in over 16s: management | CG141 | | |
Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
Palliative care for adults: strong opioids for pain relief | CG140 | | |
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation | TA398 | | |
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
Non-Hodgkin's lymphoma: diagnosis and management | NG52 | | |
Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures | CG64 | | |
Non-alcoholic fatty liver disease (NAFLD): assessment and management | NG49 | | |
Oral health for adults in care homes | NG48 | | |
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
Haematological cancers: improving outcomes | NG47 | | |
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
ImmunoCAP ISAC 112 for multiplex allergen testing | DG24 | | |
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
Controlled drugs: safe use and management | NG46 | | |
Routine preoperative tests for elective surgery | NG45 | | |
Workplace health: management practices | NG13 | | |
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
Community engagement: improving health and wellbeing and reducing health inequalities | NG44 | | |
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
Spectra Optia for automatic red blood cell exchange in people with sickle cell disease | MTG28 | | |
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
Transition from children's to adults' services for young people using health or social care services | NG43 | | |
Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) | DG22 | | |
Fractures (non-complex): assessment and management | NG38 | | |
Major trauma: assessment and initial management | NG39 | | |
Major trauma: service delivery | NG40 | | |
Spinal injury: assessment and initial management | NG41 | | |
Skin cancer prevention | PH32 | | |
Sunlight exposure: risks and benefits | NG34 | | |
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
Older people: independence and mental wellbeing | NG32 | | |
Care of dying adults in the last days of life | NG31 | | |
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
Oral health promotion: general dental practice | NG30 | | |
Transition between inpatient hospital settings and community or care home settings for adults with social care needs | NG27 | | |
Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care | NG26 | | |
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
Vortioxetine for treating major depressive episodes | TA367 | | |
Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
Blood transfusion | NG24 | | |
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions | DG19 | | |
Older people with social care needs and multiple long-term conditions | NG22 | | |
Developing and updating local formularies | MPG1 | | |
Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset | NG16 | | |
Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) | DG18 | | |
Home care: delivering personal care and practical support to older people living in their own homes | NG21 | | |
Coeliac disease: recognition, assessment and management | NG20 | | |
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use | NG15 | | |
Naloxegol for treating opioid‑induced constipation | TA345 | | |
Aflibercept for treating diabetic macular oedema | TA346 | | |
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
Lower urinary tract symptoms in men: management | CG97 | | |
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges | NG11 | | |
Violence and aggression: short-term management in mental health, health and community settings | NG10 | | |
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
Obesity prevention | CG43 | | |
Preventing excess weight gain | NG7 | | |
Excess winter deaths and illness and the health risks associated with cold homes | NG6 | | |
Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes | NG5 | | |
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy | MTG22 | | |
Safe midwifery staffing for maternity settings | NG4 | | |
Bladder cancer: diagnosis and management | NG2 | | |
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
Sofosbuvir for treating chronic hepatitis C | TA330 | | |
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
Eculizumab for treating atypical haemolytic uraemic syndrome | HST1 | | |
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment | DG16 | | |
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury | MTG21 | | |
Maternal and child nutrition | PH11 | | |
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
Gallstone disease: diagnosis and management | CG188 | | |
Oral health: local authorities and partners | PH55 | | |
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence | CG115 | | |
Physical activity: exercise referral schemes | PH54 | | |
Drug allergy: diagnosis and management | CG183 | | |
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) | DG13 | | |
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
Safe staffing for nursing in adult inpatient wards in acute hospitals | SG1 | | |
The geko device for reducing the risk of venous thromboembolism | MTG19 | | |
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
Weight management: lifestyle services for overweight or obese adults | PH53 | | |
Pressure ulcers: prevention and management | CG179 | | |
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | DG12 | | |
Contraceptive services for under 25s | PH51 | | |
Needle and syringe programmes | PH52 | | |
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
Managing medicines in care homes | SC1 | | |
Psychosis and schizophrenia in adults: prevention and management | CG178 | | |
Domestic violence and abuse: multi-agency working | PH50 | | |
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
Behaviour change: individual approaches | PH49 | | |
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
Weight management: lifestyle services for overweight or obese children and young people | PH47 | | |
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel | DG11 | | |
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer | DG9 | | |
Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer | DG8 | | |
Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
Varicose veins: diagnosis and management | CG168 | | |
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
Mirabegron for treating symptoms of overactive bladder | TA290 | | |
Falls in older people: assessing risk and prevention | CG161 | | |
Physical activity: brief advice for adults in primary care | PH44 | | |
Social anxiety disorder: recognition, assessment and treatment | CG159 | | |
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
Omalizumab for treating severe persistent allergic asthma | TA278 | | |
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
Antisocial personality disorder: prevention and management | CG77 | | |
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
Hepatitis B and C testing: people at risk of infection | PH43 | | |
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
Physical activity: walking and cycling | PH41 | | |
Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
Ivabradine for treating chronic heart failure | TA267 | | |
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M | DG6 | | |
Social and emotional wellbeing: early years | PH40 | | |
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
Alteplase for treating acute ischaemic stroke | TA264 | | |
Neutropenic sepsis: prevention and management in people with cancer | CG151 | | |
SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver | DG5 | | |
Mega Soft Patient Return Electrode for use during monopolar electrosurgery | MTG11 | | |
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
Sickle cell disease: managing acute painful episodes in hospital | CG143 | | |
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
Pharmalgen for the treatment of bee and wasp venom allergy | TA246 | | |
Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults | TA245 | | |
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services | CG136 | | |
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
Healthcare-associated infections: prevention and control | PH36 | | |
The EOS 2D/3D imaging system | DG1 | | |
Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
Mifamurtide for the treatment of osteosarcoma | TA235 | | |
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
Ambulight PDT for the treatment of non-melanoma skin cancer | MTG6 | | |
The MIST Therapy system for the promotion of wound healing | MTG5 | | |
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
Type 2 diabetes prevention: population and community-level interventions | PH35 | | |
Golimumab for the treatment of psoriatic arthritis | TA220 | | |
Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings | CG120 | | |
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
Food allergy in under 19s: assessment and diagnosis | CG116 | | |
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
Sedation in under 19s: using sedation for diagnostic and therapeutic procedures | CG112 | | |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
Prucalopride for the treatment of chronic constipation in women | TA211 | | |
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
Unintentional injuries: prevention strategies for under 15s | PH29 | | |
Unintentional injuries in the home: interventions for under 15s | PH30 | | |
Unintentional injuries on the road: interventions for under 15s | PH31 | | |
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
Bedwetting in under 19s | CG111 | | |
Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors | CG110 | | |
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
Weight management before, during and after pregnancy | PH27 | | |
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
Cardiovascular disease prevention | PH25 | | |
Alcohol-use disorders: prevention | PH24 | | |
Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
Improving outcomes for people with skin tumours including melanoma | CSG8 | | |
Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
Donor milk banks: service operation | CG93 | | |
Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
Depression in adults with a chronic physical health problem: recognition and management | CG91 | | |
Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
Guidance on the use of electroconvulsive therapy | TA59 | | |
Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management | CG84 | | |
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | TA170 | | |
Rehabilitation after critical illness in adults | CG83 | | |
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence | CG76 | | |
Borderline personality disorder: recognition and management | CG78 | | |
Physical activity for children and young people | PH17 | | |
Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
Mental wellbeing in over 65s: occupational therapy and physical activity interventions | PH16 | | |
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
Cardiovascular disease: identifying and supporting people most at risk of dying early | PH15 | | |
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults | TA157 | | |
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
Entecavir for the treatment of chronic hepatitis B | TA153 | | |
Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
Adalimumab for the treatment of adults with psoriasis | TA146 | | |
Physical activity in the workplace | PH13 | | |
Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over | TA138 | | |
Structural neuroimaging in first-episode psychosis | TA136 | | |
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma | TA137 | | |
Infliximab for the treatment of adults with psoriasis | TA134 | | |
Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years | TA131 | | |
Behaviour change: general approaches | PH6 | | |
Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
Acutely ill adults in hospital: recognising and responding to deterioration | CG50 | | |
Drug misuse in over 16s: opioid detoxification | CG52 | | |
Drug misuse in over 16s: psychosocial interventions | CG51 | | |
Varenicline for smoking cessation | TA123 | | |
Faecal incontinence in adults: management | CG49 | | |
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
Naltrexone for the management of opioid dependence | TA115 | | |
Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
Laparoscopic surgery for colorectal cancer | TA105 | | |
Etanercept and efalizumab for the treatment of adults with psoriasis | TA103 | | |
Improving outcomes for people with brain and other central nervous system tumours | CSG10 | | |
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer | TA100 | | |
Improving outcomes for people with sarcoma | CSG9 | | |
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
Obsessive-compulsive disorder and body dysmorphic disorder: treatment | CG31 | | |
Improving outcomes in children and young people with cancer | CSG7 | | |
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
Improving outcomes in head and neck cancers | CSG6 | | |
Dental checks: intervals between oral health reviews | CG19 | | |
Laparoscopic surgery for inguinal hernia repair | TA83 | | |
Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
Improving supportive and palliative care for adults with cancer | CSG4 | | |
Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
Improving outcomes in urological cancers | CSG2 | | |
Improving outcomes in breast cancer | CSG1 | | |
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) | TA38 | | |
Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma | TA10 | | |
Guidance on the extraction of wisdom teeth | TA1 | | |